Current Report Filing (8-k)
September 02 2016 - 5:13PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event
Reported): September 1, 2016
PANTHER
BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-55074
|
|
33-1221758
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
888 Prospect Street, Suite 200, La Jolla, CA
|
|
92037
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(858) 263-2744
(Registrant’s telephone number, including
area code)
(Former name if changed since last report)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.
|
(a)
|
Dismissal of GBH CPAs, P.C.
|
On September 1, 2016,
the Board of Directors of Panther Biotechnology, Inc. (the “Registrant” or the ‘Company”) dismissed GBH
CPAs, P.C. (“GBH”) as its independent registered public accounting firm.
The report of GBH
on the Company’s financial statements for the fiscal years ended May 31, 2015 and 2014 did not contain any adverse
opinion or disclaimer of opinion, nor was it qualified or modified as to audit scope or accounting principles. The report did
include an explanatory paragraph about the uncertainty as to the Registrant's ability to continue as a going concern. During the
period of GBH’s engagement as the Company’s independent registered public accounting firm through September 1, 2016
(the “Engagement Period”), there were no disagreements as defined in Item 304 of Regulation S-K with PMB on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if
not resolved to the satisfaction of GBH, would have caused it to make reference in connection with any opinion to the subject
matter of the disagreement. Further, during the Engagement Period, there were no reportable events (as defined in Item 304(a)(1)(v)
of Regulation S-K).
The Registrant has provided GBH with a copy of this Report prior to its filing with the SEC and requested GBH
to furnish the Registrant with a letter addressed to the SEC, stating whether or not it agrees with the statements made above.
A copy of GBH’s letter dated September 1, 2016, confirming its agreement with the disclosures in this Item 401 is attached
as Exhibit 16.1 to this Form 8-K.
|
(b)
|
Engagement of LBB & Associates Ltd, LLP (“LBB”)
|
On September 1, 2016,
the Board of Directors appointed LBB & Associates Ltd, LLP (“LBB”), an independent registered public accounting
firm which is registered with, and governed by the rules of, the Public Company Accounting Oversight Board, as our independent
registered public accounting firm. During our two most recent fiscal years through May 31, 2015, neither us nor anyone on
our behalf consulted LLB regarding either (1) the application of accounting principles to a specified transaction regarding us,
either completed or proposed, or the type of audit opinion that might be rendered on our financial statements; or (2) any matter
regarding us that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions
to Item 304 of Regulation S-K) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).
Item 9.01 Financial Statements and Exhibits
(a) Financial statements of businesses acquired.
Not applicable
(b) Pro forma financial information.
Not applicable
(c) Shell company
transactions.
Not applicable
(d) Exhibits
Exhibit No.
|
|
Description of Exhibit
|
16.1
|
|
Letter from GBH CPAs, P.C.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
PANTHER BIOTECHNOLOGY, INC.
|
|
|
|
Dated: September 1, 2016
|
By:
|
/s/ Evan Levine
|
|
|
Name: Evan Levine
|
|
|
Title: Chief Executive Officer
|
Probility Media (CE) (USOTC:PBYA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Probility Media (CE) (USOTC:PBYA)
Historical Stock Chart
From Apr 2023 to Apr 2024